Showing 3,801 - 3,820 results of 5,570 for search '"Oncology"', query time: 0.11s Refine Results
  1. 3801
  2. 3802
  3. 3803
  4. 3804
  5. 3805
  6. 3806

    PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study by He Z, Chen H, Liang C, Tang X, Jiang L, Xie F, Liu Q, Zheng Y

    Published 2025-01-01
    “…Zhaoqian He,1– 3,* Hua Chen,1– 3,* Chen Liang,1– 3,* Xiang Tang,1– 3 Lingmin Jiang,1– 3 Feihu Xie,1– 3 Qi Liu,1– 3 Yun Zheng1– 3 1Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 2Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 3Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yun Zheng; Qi Liu, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People’s Republic of China, Email zhengyun@sysucc.org.cn; liuqi9@sysucc.org.cnPurpose: To compare the clinical outcomes of different systemic therapies, specifically PD(L)1 inhibitors plus Lenvatinib versus Atezolizumab plus Bevacizumab, when combined with hepatic arterial infusion chemotherapy (HAIC) based on the FOLFOX regimen (oxaliplatin, fluorouracil, and leucovorin) as first line treatment for unresectable hepatocellular carcinoma.Patients and Methods: This real-world retrospective study enrolled 294 patients with unresectable HCC. …”
    Get full text
    Article
  7. 3807
  8. 3808
  9. 3809

    A Path to High-Value Gastric Cancer Surgery Care Delivery by Swee H. Teh, MD, Sharon Shiraga, MD, Aaron M. Kellem, BS (Math), Robert A. Li, MD, David M. Le, MD, Said P. Arsalane, MSHA, Fawzi S. Khayat, MD, Yan Li, MD, I-Yeh Gong, MD, Jessica M. Lee, MD

    Published 2024-06-01
    “…This comprehensive regional program, which encompasses regionalization care, laparoscopic approach, modern oncologic care, surgical subspecialization, and the MIREC pathway, can potentially improve gastric cancer surgery outcomes. …”
    Get full text
    Article
  10. 3810
  11. 3811
  12. 3812
  13. 3813
  14. 3814
  15. 3815
  16. 3816
  17. 3817
  18. 3818

    Increased dicentric chromosome in peripheral lymphocytes is related to acute skin toxicity induced by radiotherapy in cancer patients by Minjie Li, Yu Gao, Lin Han, Ping Wang, Jie Li, Junhua Song, Shasha Du, Yunfei Zhang, Yumin Lyu

    Published 2025-02-01
    “…These patients were grouped according to the grade of acute skin and marrow toxicities determined based on the scoring criteria for acute morbidity developed by the Radiation Therapy Oncology Group (RTOG). Peripheral blood samples were collected from each patient before and after RT, followed by whole-blood lymphocyte culture and chromosome analysis. …”
    Get full text
    Article
  19. 3819
  20. 3820